Singh Vinayak
Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa; South African Medical Research Council Drug Discovery and Development Research Unit, University of Cape Town, Rondebosch 7701, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Observatory 7925, South Africa.
Drug Discov Today. 2024 May;29(5):103955. doi: 10.1016/j.drudis.2024.103955. Epub 2024 Mar 26.
Tuberculosis (TB) presents a significant global health concern, with ∼10 million people developing TB and 1.3 million people dying from the disease each year. The standard treatment regimen for drug-susceptible TB was between 6 and 9 months until recently, presenting a prolonged therapeutic duration compared with other infectious diseases. This is a long time for patients to adhere to the medication, consequently increasing the risk of developing drug-resistant Mycobacterium tuberculosis - a significant challenge in TB management globally. Therefore, the primary objective of contemporary TB drug development research is to shorten the treatment duration. This review comprehensively explores the strategies aimed at shortening TB treatment.
结核病是一个重大的全球卫生问题，每年约有1000万人患结核病，130万人死于该病。直到最近，药物敏感型结核病的标准治疗方案疗程为6至9个月，与其他传染病相比，治疗时间较长。患者需要长时间坚持服药，因此增加了产生耐多药结核分枝杆菌的风险，这是全球结核病管理中的一项重大挑战。因此，当代结核病药物研发的主要目标是缩短治疗时间。本综述全面探讨了旨在缩短结核病治疗时间的策略。
